- Proteasome inhibitors are a class of compounds that block the proteolytic activity of the proteasome, preventing the degradation of ubiquitinated proteins. By interfering with the ubiquitin–proteasome system, these inhibitors disrupt protein turnover, alter signalling pathways, and induce cellular stress responses. Proteasome inhibitors have become powerful therapeutic agents, particularly in cancer treatment, where they trigger apoptosis in rapidly dividing cells. Their ability to modulate protein homeostasis makes them essential tools in biomedical research and clinical therapy.
- Proteasome inhibitors primarily target the 20S proteasome, the catalytic core responsible for peptide bond cleavage. Most clinically used inhibitors bind to the β5 subunit, which possesses chymotrypsin‑like activity. By blocking this active site, inhibitors prevent the degradation of regulatory proteins involved in cell‑cycle control, apoptosis, and stress responses. Some inhibitors also affect the β1 and β2 subunits, altering caspase‑like and trypsin‑like activities. This broad inhibition disrupts multiple cellular pathways, leading to accumulation of misfolded proteins and activation of the unfolded protein response.
- The first‑generation proteasome inhibitor bortezomib revolutionised cancer therapy. It reversibly inhibits the β5 subunit and is widely used to treat multiple myeloma and mantle cell lymphoma. Carfilzomib, a second‑generation inhibitor, binds irreversibly to the proteasome and offers improved potency and reduced off‑target effects. Ixazomib, an orally available inhibitor, provides greater convenience for long‑term treatment. These drugs exploit the dependence of cancer cells on high proteasome activity, making them particularly effective against malignancies with elevated protein turnover.
- Proteasome inhibitors induce apoptosis through several mechanisms. By preventing degradation of pro‑apoptotic factors, they shift the balance towards cell death. They also inhibit NF‑κB signalling by stabilising its inhibitor, IκB, reducing transcription of survival genes. Additionally, accumulation of misfolded proteins triggers endoplasmic reticulum stress and activates the unfolded protein response, ultimately leading to apoptosis. These combined effects make proteasome inhibitors highly effective against cancer cells, which rely on rapid protein synthesis and turnover.
- Beyond oncology, proteasome inhibitors have potential applications in autoimmune diseases, inflammatory disorders, and viral infections. By modulating immune signalling, they can reduce excessive cytokine production and dampen inflammatory responses. Research is ongoing to explore their use in conditions such as rheumatoid arthritis, lupus, and graft‑versus‑host disease. However, their immunosuppressive effects require careful clinical management.
- Proteasome inhibitors also provide valuable insight into protein homeostasis and cellular stress responses. By blocking proteasomal degradation, researchers can study the roles of specific proteins, investigate signalling pathways, and explore mechanisms of proteotoxicity. These inhibitors are essential tools for understanding diseases characterised by protein aggregation, including neurodegenerative disorders.
- Despite their therapeutic benefits, proteasome inhibitors can cause side effects such as neuropathy, fatigue, and gastrointestinal disturbances. These arise from the essential role of the proteasome in normal cellular function. Ongoing research aims to develop more selective inhibitors, reduce toxicity, and improve clinical outcomes.
- Overall, proteasome inhibitors are powerful modulators of protein degradation and cellular regulation. Their ability to disrupt proteasome activity has transformed cancer therapy and expanded our understanding of protein homeostasis. As research advances, proteasome inhibitors will continue to play a central role in therapeutic innovation and molecular medicine.
